scholarly journals Trait Anxiety as a Risk Factor for Impulse Control Disorders in de novo Parkinson’s Disease

2021 ◽  
pp. 1-9
Author(s):  
Pauline Waskowiak ◽  
Vincent Koppelmans ◽  
Marit F.L. Ruitenberg
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Risk Factor ◽  
Trait Anxiety ◽  
Impulse Control ◽  
De Novo ◽  
Impulse Control Disorders ◽  
Motor Symptoms ◽  
Depression And Anxiety

Background: In addition to the well-known motor symptoms, patients with Parkinson’s disease (PD) also frequently experience disabling non-motor symptoms including impulse control disorders (ICDs). ICDs are characterized by a loss of voluntary control over impulses, drives, or temptations regarding excessive hedonic behavior. Objective: The present study examined whether depression and anxiety in de novo PD patients predict the prospective development of ICDs. Methods: We selected 330 de novo PD patients from the Parkinson’s Progression Markers Initiative database who were free of ICDs at the start of the study. ICD presence at baseline and follow-up assessments was evaluated via the shortened version of the Questionnaire for Impulsive-Compulsive Disorders (QUIP-S). Baseline depression and anxiety were measured via the Geriatric Depression Scale (GDS-15) and State-Trait-Anxiety Inventory (STAI-Y), respectively. Results: A total of 149 participants (45.2%) developed an ICD at follow-up and average time of ICD onset was 35 months after baseline. Results of a Cox regression analysis showed that STAI-Y scores but not GDS-15 scores significantly predicted ICD presence. Specifically, scores reflecting higher trait anxiety were associated with an increased risk of developing an ICD. This effect was not confounded by age, gender or UPDRS motor score. We also replicated the well-established result that dopamine agonist use is predictive of ICDs. Conclusion: Our findings indicate that higher anxiety levels in de novo PD patients represent a risk factor for ICD development during the course of the disorder. This highlights the need for early and routine based anxiety screening in these patients.

scholarly journals Trait anxiety as a risk factor for impulse control disorders in de novo Parkinson’s disease

2021 ◽  
Author(s):  
Pauline Waskowiak ◽  
Vincent Koppelmans ◽  
Marit Ruitenberg
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Risk Factor ◽  
Trait Anxiety ◽  
Impulse Control ◽  
De Novo ◽  
Impulse Control Disorders ◽  
Motor Symptoms ◽  
Increased Risk

Background: In addition to the well-known motor symptoms, patients with Parkinson’s disease (PD) also frequently experience disabling non-motor symptoms including impulse control disorders (ICDs). ICDs are character-ized by a loss of voluntary control over impulses, drives, or temptations regarding excessive hedonic behavior. Objective: The present study exam-ined whether depression and anxiety in de novo PD patients predict the prospective development of ICDs. Methods: We selected 334 de novo PD patients from the Parkinson’s Progression Markers Initiative database who were free of ICDs at the start of the study. ICD presence at baseline and follow-up assessments was evaluated via the shortened version of the Questionnaire for Impulsive‐Compulsive Disorders (QUIP-S). Baseline de-pression and anxiety were measured via the Geriatric Depression Scale (GDS-15) and State-Trait-Anxiety Inventory (STAI-Y), respectively. Results: A total of 149 participants (45.2%) developed an ICD at follow-up and av-erage time of ICD onset was 35 months after baseline. Results of a Cox re-gression analysis showed that STAI-Y scores but not GDS-15 scores signifi-cantly predicted ICD presence. Specifically, scores reflecting higher trait anxiety were associated with an increased risk of developing an ICD. This effect was not confounded by age, gender or UPDRS motor score. We also replicated the well-established result that dopamine agonist use is predic-tive of ICDs. Conclusions: Our findings indicate that higher anxiety levels in de novo PD patients represent a risk factor for ICD development during the course of the disorder. This highlights the need for early and routine based anxiety screening in these patients.

Impact of gender on impulse control disorders and other non-motor symptoms among Parkinson's disease patients

2016 ◽  
Vol 22 ◽  
pp. e8
Author(s):  
Norbert Kovács ◽  
Gebriella Deli ◽  
Zsuzsanna Aschermann ◽  
Attila Makkos ◽  
József Janszky ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impulse Control ◽  
Impulse Control Disorders ◽  
Motor Symptoms ◽  
Non Motor Symptoms

Long term follow-up of Parkinson's disease patients with impulse control disorders

2010 ◽  
Vol 16 (5) ◽  
pp. 334-337 ◽  
Author(s):  
Melis Sohtaoğlu ◽  
Derya Yavuz Demiray ◽  
Gülay Kenangil ◽  
Sibel Özekmekçi ◽  
Ethem Erginöz
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impulse Control ◽  
Impulse Control Disorders ◽  
Long Term Follow Up

Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders

2015 ◽  
Vol 30 (5) ◽  
pp. 696-704 ◽  
Author(s):  
Chiara Siri ◽  
Roberto Cilia ◽  
Elisa Reali ◽  
Beatrice Pozzi ◽  
Emanuele Cereda ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impulse Control ◽  
Impulse Control Disorders

scholarly journals Long-term follow-up of impulse control disorders in Parkinson's disease

2008 ◽  
Vol 23 (1) ◽  
pp. 75-80 ◽  
Author(s):  
Eugenia Mamikonyan ◽  
Andrew D. Siderowf ◽  
John E. Duda ◽  
Marc N. Potenza ◽  
Stacy Horn ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impulse Control ◽  
Impulse Control Disorders ◽  
Long Term Follow Up

Apathy and impulse control disorders association: A study in a sample of Parkinson's disease patients

2016 ◽  
Vol 33 (S1) ◽  
pp. S396-S396
Author(s):  
N. Sáez-Francàs ◽  
N. Ramirez ◽  
J. Alegre-Martin ◽  
O. De Fabregues ◽  
J. Alvarez-Sabin ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Trait Anxiety ◽  
Impulse Control ◽  
Rating Scale ◽  
Neurodegenerative Disorder ◽  
Linear Regression Analysis ◽  
Impulse Control Disorders ◽  
Hamilton Depression Scale ◽  
Wide Range

IntroductionParkinson's disease (PD) is a neurodegenerative disorder that is associated with a wide range of motor symptoms, cognitive deficits and behavioral disorders. Apathy and impulse control disorders (ICDs) are common in these patients and have been considered opposite ends of a reward and motivation disorders continuum.AimTo evaluate the association and impact of ICDs presence on apathy symptoms in PDs patients, considering the influence of other psychopathological symptoms on this association.MethodsThis is a cross-sectional, observational study in which 115 consecutive medicated PD patients without dementia (mean age 61.22 ± 13.5 years; 63.5% men) were recruited. All the patients underwent a psychiatric and neurologic evaluation. Motor dysfunction was assessed with the Unified Parkinson's disease Rating Scale (UPDRS), ICDs were evaluated with the Minnesota Impulse Control Disorders Inventory (MIDI) and apathy with the Lille Apathy Scale (LARS). The Hamilton Depression scale (HAM-D). The State-Trait Anxiety Inventory (STAI-S) and Barrat Impulsivity Scale (BIS) were also administrated.ResultsTwenty-seven (23.5%) patients showed an ICD. Patients with an ICD scored higher in apathy (P = 0.012), trait anxiety (P = 0.003) and impulsivity (P = 0.008). There were no differences in depressive symptoms. In the linear regression analysis, TCI was associated with more severe apathy (b = 4.20, t = 2.15, P = 0.034).ConclusionsICDs and apathy are frequent in PD. Although ICDs have been related with a hyperdopaminergic state and apathy with low dopamine levels, the observed frequent association suggests common etiopathological mechanisms.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort study

2018 ◽  
Vol 89 (8) ◽  
pp. 836-843 ◽  
Author(s):  
Marie Abbes ◽  
Eugénie Lhommée ◽  
Stéphane Thobois ◽  
Hélène Klinger ◽  
Emmanuelle Schmitt ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Impulse Control ◽  
Neuropsychiatric Symptoms ◽  
Impulse Control Disorders ◽  
Subthalamic Stimulation ◽  
Deep Brain

BackgroundReports on behavioural outcomes after subthalamic nucleus deep brain stimulation in Parkinson’s disease are controversial and limited to short-term data. Long-term observation in a large cohort allows a better counselling and management.MethodsTo determine whether a long-term treatment with subthalamic stimulation induces or reduces impulse control behaviours, neuropsychiatric fluctuations and apathy, 69 patients treated with subthalamic stimulation are prospectively and retrospectively assessed using Ardouin Scale of Behavior in Parkinson’s Disease before and after 3–10 years of stimulation.ResultsAt a mean follow-up of 6 years, all impulse control disorders and dopaminergic addiction were significantly decreased, apart from eating behaviour and hypersexuality. Neuropsychiatric fluctuations also significantly improved (ON euphoria: 38% of the patients before surgery and 1% after surgery, P<0.01; OFF dysphoria: 39% of the patients before surgery and 10% after surgery, P<0.01). However, apathy increased (25% of the patients after surgery and 3% before, P<0.01). With the retrospective analysis, several transient episodes of depression, apathy, anxiety and impulse control disorders occurred.ConclusionsBilateral subthalamic nucleus stimulation was overall very effective in improving impulse control disorders and neuropsychiatric fluctuations in parkinsonian patients in the long term despite a counteracting frequent apathy. Transient episodes of impulse control disorders still occurred within the follow-up. These findings recommend a close follow-up in parkinsonian patients presenting with neuropsychiatric symptoms before deep brain stimulation surgery.Clinical trial registrationNCT01705418;Post-results.

scholarly journals Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson’s disease patients for the identification and validation of biomarkers for Parkinson’s disease subtypes, progression and pathophysiology

BMC Neurology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Jeffrey M. Boertien ◽  
◽  
Sygrid van der Zee ◽  
Asterios Chrysou ◽  
Marleen J. J. Gerritsen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Study ◽  
Pet Imaging ◽  
De Novo ◽  
Gastrointestinal Function ◽  
Motor Symptoms ◽  
Treatment Naïve ◽  
Non Motor Symptoms

Abstract Background Parkinson’s Disease (PD) is a heterogeneous, progressive neurodegenerative disorder which is characterized by a variety of motor and non-motor symptoms. To date, no disease modifying treatment for PD exists. Here, the study protocol of the Dutch Parkinson Cohort (DUPARC) is described. DUPARC is a longitudinal cohort study aimed at deeply phenotyping de novo PD patients who are treatment-naïve at baseline, to discover and validate biomarkers for PD progression, subtypes and pathophysiology. Methods/design DUPARC is a prospective cohort study in which 150 de novo PD subjects will be recruited through a collaborative network of PD treating neurologists in the northern part of the Netherlands (Parkinson Platform Northern Netherlands, PPNN). Participants will receive follow-up assessments after 1 year and 3 years, with the intention of an extended follow-up with 3 year intervals. Subjects are extensively characterized to primarily assess objectives within three major domains of PD: cognition, gastrointestinal function and vision. This includes brain magnetic resonance imaging (MRI); brain cholinergic PET-imaging with fluoroethoxybenzovesamicol (FEOBV-PET); brain dopaminergic PET-imaging with fluorodopa (FDOPA-PET); detailed neuropsychological assessments, covering all cognitive domains; gut microbiome composition; intestinal wall permeability; optical coherence tomography (OCT); genotyping; motor and non-motor symptoms; overall clinical status and lifestyle factors, including a dietary assessment; storage of blood and feces for additional analyses of inflammation and metabolic parameters. Since the start of the inclusion, at the end of 2017, over 100 PD subjects with a confirmed dopaminergic deficit on FDOPA-PET have been included. Discussion DUPARC is the first study to combine data within, but not limited to, the non-motor domains of cognition, gastrointestinal function and vision in PD subjects over time. As a de novo PD cohort, with treatment naïve subjects at baseline, DUPARC provides a unique opportunity for biomarker discovery and validation without the possible confounding influences of dopaminergic medication. Trial registration NCT04180865; registered retrospectively, November 28th 2019.

Sign in / Sign up

Export Citation Format

Share Document